文献速递其他结缔组织病

基于自身抗体与皮肤亚型构建系统性硬化症结局导向分类

Using Autoantibodies and Cutaneous Subset to Develop Outcome-Based Disease Classification in Systemic Sclerosis.
PubMed 文献 · Arthritis Rheumatol · 2020-01-28

该研究纳入1325例系统性硬化症患者,分析自身抗体、皮肤亚型与器官并发症及生存的关联,提出结合抗体和皮肤亚型的新型分类方案,以改善疾病监测和临床试验设计。

要点

  • 抗着丝点抗体阳性局限型皮肤SSc患者20年生存率最高(65.3%),肺纤维化和肾危象发生率最低。
  • 抗Scl-70抗体阳性弥漫型皮肤SSc患者15年临床显著肺纤维化发生率84%,20年生存率最低(32.4%)。
  • 抗RNA聚合酶抗体阳性患者20年肾危象发生率最高(28.1%),抗U3 RNP抗体阳性患者20年肺动脉高压发生率最高(33.8%)。

核心结论

  • 自身抗体、皮肤亚型和疾病病程对评估SSc患者发病率和死亡率至关重要。
  • 新型分类方案可能改善疾病监测并有益于未来临床试验设计。

研究设计与样本

  • 队列研究,纳入1325例系统性硬化症患者,分析人口学与临床特征、皮肤亚型、疾病及器官并发症发生时间和自身抗体特异性。
  • 采用生存分析评估自身抗体对器官疾病和死亡的影响。

主要发现

  • 抗着丝点抗体阳性局限型皮肤SSc患者(n=374)20年生存率最高(65.3%),临床显著肺纤维化发生率8.5%,肾危象发生率0.3%,心脏SSc发生率4.9%。
  • 抗Scl-70抗体阳性局限型皮肤SSc患者(n=138)和弥漫型皮肤SSc患者(n=149)15年临床显著肺纤维化发生率分别为86.1%和84%。
  • 抗Scl-70抗体阳性弥漫型皮肤SSc患者20年生存率最低(32.4%),心脏SSc发生率第二高(12.9%)。
  • 抗Scl-70抗体阳性局限型皮肤SSc患者20年肺动脉高压发生率最低(6.9%),生存率第二高(61.8%)。
  • 抗RNA聚合酶抗体阳性患者(n=147)20年肾危象发生率最高(28.1%);抗U3 RNP抗体阳性患者(n=56)20年肺动脉高压发生率最高(33.8%),心脏SSc发生率13.2%。

临床怎么用

  • 利用自身抗体和皮肤亚型联合分类可识别不同器官并发症和死亡风险的患者亚群,指导个体化监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To describe the associations between autoantibodies, clinical presentation, and outcomes among patients with systemic sclerosis (SSc) in order to develop a novel SSc classification scheme that would incorporate both antibodies and the cutaneous disease subset as criteria. METHODS: Demographic and clinical characteristics, including cutaneous subset, time of disease and organ complication onset, and autoantibody specificities, were determined in a cohort of SSc subjects. Survival analysis was used to assess the effect of the autoantibodies on organ disease and death. RESULTS: The study included 1,325 subjects. Among the antibody/skin disease subsets, anticentromere antibody-positive patients with limited cutaneous SSc (lcSSc) (n = 374) had the highest 20-year survival (65.3%), lowest incidence of clinically significant pulmonary fibrosis (PF) (8.5%) and scleroderma renal crisis (SRC) (0.3%), and lowest incidence of cardiac SSc (4.9%), whereas the frequency of pulmonary hypertension (PH) was similar to the mean value in the SSc cohort overall. The anti-Scl-70+ groups of patients with lcSSc (n = 138) and patients with diffuse cutaneous SSc (dcSSc) (n = 149) had the highest incidence of clinically significant PF (86.1% and 84%, respectively, at 15 years). Anti-Scl-70+ patients with dcSSc had the lowest survival (32.4%) and the second highest incidence of cardiac SSc (12.9%) at 20 years. In contrast, in anti-Scl-70+ patients with lcSSc, other complications were rare, and these patients demonstrated the lowest incidence of PH (6.9%) and second highest survival (61.8%) at 20 years. Anti-RNA polymerase antibody-positive SSc patients (n = 147) had the highest incidence of SRC (28.1%) at 20 years. The anti-U3 RNP+ SSc group (n = 56) had the highest incidence of PH (33.8%) and cardiac SSc (13.2%) at 20 years. Among lcSSc patients with other autoantibodies (n = 295), the risk of SRC and cardiac SSc was low at 20 years (2.7% and 2.4%, respectively), while the frequencies of other outcomes were similar to the mean values in the full SSc cohort. Patients with dcSSc who were positive for other autoantibodies (n = 166) had a poor prognosis, demonstrating the second lowest survival (33.6%) and frequent organ complications. CONCLUSION: These findings highlight the importance of autoantibodies, cutaneous subset, and disease duration when assessing morbidity and mortality in patients with SSc. Our novel classification scheme may improve disease monitoring and benefit future clinical trial designs in SSc.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Nihtyanova SI, Sari A, Harvey JC, et al. Using Autoantibodies and Cutaneous Subset to Develop Outcome-Based Disease Classification in Systemic Sclerosis. Arthritis Rheumatol. 2020. PMID: 31682743. doi:10.1002/art.41153

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。